217 related articles for article (PubMed ID: 29748619)
21. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
22. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
23. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
24. The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.
Tian L; Peng Y; Yang K; Cao J; Du X; Liang Z; Shi J; Zhang J
Cell Commun Signal; 2022 Nov; 20(1):178. PubMed ID: 36376959
[TBL] [Abstract][Full Text] [Related]
25. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
27. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
28. Arrestin2 modulates androgen receptor activation.
Purayil HT; Zhang Y; Dey A; Gersey Z; Espana-Serrano L; Daaka Y
Oncogene; 2015 Jun; 34(24):3144-51. PubMed ID: 25109335
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
[TBL] [Abstract][Full Text] [Related]
30. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of Eukaryotic Initiation Factor 4G1 (eIF4G1) at Ser1147 Is Specific for eIF4G1 Bound to eIF4E in Delayed Neuronal Death after Ischemia.
Martínez-Alonso E; Guerra-Pérez N; Escobar-Peso A; Peracho L; Vera-Lechuga R; Cruz-Culebras A; Masjuan J; Alcázar A
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163752
[TBL] [Abstract][Full Text] [Related]
32. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
33. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
34. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
35. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract][Full Text] [Related]
36. Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth.
Zhu YP; Wan FN; Shen YJ; Wang HK; Zhang GM; Ye DW
Oncotarget; 2015 Jun; 6(16):14488-96. PubMed ID: 25895032
[TBL] [Abstract][Full Text] [Related]
37. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
38. PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2.
Zhao R; Feng T; Gao L; Sun F; Zhou Q; Wang X; Liu J; Zhang W; Wang M; Xiong X; Jia W; Chen W; Wang L; Han B
J Exp Clin Cancer Res; 2022 Apr; 41(1):125. PubMed ID: 35382861
[TBL] [Abstract][Full Text] [Related]
39. [Role of eukaryotic translation initiation factor 4G in tumor].
Zhang S; Huang N; Pan X; Zang JL; Guan XX; Zhang JH; Liu LC; Lei XY
Sheng Li Xue Bao; 2016 Apr; 68(2):207-14. PubMed ID: 27108909
[TBL] [Abstract][Full Text] [Related]
40. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.
Clermont PL; Crea F; Chiang YT; Lin D; Zhang A; Wang JZ; Parolia A; Wu R; Xue H; Wang Y; Ding J; Thu KL; Lam WL; Shah SP; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2016; 8():16. PubMed ID: 26877821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
